COVID-19 in heart transplant recipients.

IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Sepideh Taghavi, Hoda Raffiei Jelodar, Ali Rafati, Nasim Naderi, Marzieh Mirtajaddini, Ahmad Amin, Leili Valizadeh, Razieh Omidvar, Monireh Kamali, Soroush Naseh
{"title":"COVID-19 in heart transplant recipients.","authors":"Sepideh Taghavi,&nbsp;Hoda Raffiei Jelodar,&nbsp;Ali Rafati,&nbsp;Nasim Naderi,&nbsp;Marzieh Mirtajaddini,&nbsp;Ahmad Amin,&nbsp;Leili Valizadeh,&nbsp;Razieh Omidvar,&nbsp;Monireh Kamali,&nbsp;Soroush Naseh","doi":"10.34172/jcvtr.2022.31583","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Introduction:</i></b> After solid organ transplantation, patients require lifelong immunosuppressive medication, increasing susceptibility to COVID-19. We evaluated the clinical outcomes of heart transplant recipients in patients with COVID-19. <b><i>Methods:</i></b> We enrolled twenty-two COVID-19 cases of adult heart transplantation from February 2020 to September 2021. <b><i>Results:</i></b> The most common symptoms in patients were fever and myalgia. The death occurred in 3 (13.6 %). <b><i>Conclusion:</i></b> Although heart transplantation mortality may increase in the acute rejection phase concomitant with COVID-19, immunosuppressive dose reduction may not be necessary for all heart transplant patients with COVID-19.</p>","PeriodicalId":15207,"journal":{"name":"Journal of Cardiovascular and Thoracic Research","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871157/pdf/","citationCount":"8","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiovascular and Thoracic Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/jcvtr.2022.31583","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 8

Abstract

Introduction: After solid organ transplantation, patients require lifelong immunosuppressive medication, increasing susceptibility to COVID-19. We evaluated the clinical outcomes of heart transplant recipients in patients with COVID-19. Methods: We enrolled twenty-two COVID-19 cases of adult heart transplantation from February 2020 to September 2021. Results: The most common symptoms in patients were fever and myalgia. The death occurred in 3 (13.6 %). Conclusion: Although heart transplantation mortality may increase in the acute rejection phase concomitant with COVID-19, immunosuppressive dose reduction may not be necessary for all heart transplant patients with COVID-19.

心脏移植受者的COVID-19
实体器官移植后,患者需要终身免疫抑制药物治疗,增加了对COVID-19的易感性。我们评估了COVID-19患者心脏移植受者的临床结果。方法:我们从2020年2月至2021年9月招募了22例COVID-19成人心脏移植病例。结果:患者最常见的症状为发热和肌痛。死亡3例(13.6%)。结论:尽管COVID-19合并急性排斥期心脏移植死亡率可能增加,但并非所有COVID-19心脏移植患者都需要减少免疫抑制剂量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Cardiovascular and Thoracic Research
Journal of Cardiovascular and Thoracic Research CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
2.00
自引率
0.00%
发文量
22
审稿时长
7 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信